Trials / Completed
CompletedNCT03169972
ADYNOVATE Drug Use-Results Survey
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 135 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this survey is to understand the following items in the actual clinical use of ADYNOVATE in patients: 1. Unexpected adverse drug reactions 2. Occurrence of adverse drug reactions in the actual clinical use 3. Factors that may affect safety and efficacy 4. Occurrence of Factor VIII inhibitor development in patients with coagulation factor VIII deficiency (hereinafter hemophilia A) 5. Safety and efficacy for hemophilia A patients who received routine prophylactic therapy and on-demand therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ADYNOVATE | Antihemophilic Factor (Recombinant), PEGylated |
Timeline
- Start date
- 2017-02-01
- Primary completion
- 2023-09-15
- Completion
- 2023-09-15
- First posted
- 2017-05-30
- Last updated
- 2025-02-04
- Results posted
- 2025-02-04
Locations
52 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03169972. Inclusion in this directory is not an endorsement.